Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infanrix Hexa
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Infanrix Hexa is a hexavalent vaccine developed by GSK for the primary and booster vaccination of infants and toddlers. It provides protection against six major pediatric diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio), and invasive diseases caused by Haemophilus influenzae type b (Hib). The vaccine is a combination of diphtheria toxoid, tetanus toxoid, three purified pertussis antigens (pertussis toxoid, filamentous haemagglutinin, and pertactin), the purified major surface antigen (HBsAg) of the hepatitis B virus, inactivated poliovirus (types 1, 2, and 3), and Hib capsular polysaccharide conjugated to tetanus toxoid. It is frequently co-administered with pneumococcal conjugate vaccines (such as Synflorix) and rotavirus vaccines (such as Rotarix) in standard pediatric immunization schedules. Clinical studies have evaluated its safety and immunogenicity when given alongside these vaccines, including the impact of prophylactic antipyretics on febrile reactions.
- Brand names
- Infanrix Hexa
- Other names
- DTaP-HBV-IPV/Hib vaccineHexavalent vaccineDiphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine
02
Targets
FHA (Filamentous hemagglutinin)HBsAg (Hepatitis B surface antigen)Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Infanrix Hexa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infanrix Hexa.